The Role of Probiotics in the Treatment of Dysentery: a Randomized Double-Blind Clinical Trial

Probiotics Antimicrob Proteins. 2017 Dec;9(4):380-385. doi: 10.1007/s12602-017-9271-0.


Diarrhea is considered as an important cause of morbidity and mortality, even though one of the main reasons of death following diarrhea is initiated by dysentery. In recent years, the consumption of probiotics has been proposed for the treatment of infectious diarrhea. Despite most of the studies on probiotics have focused on acute watery diarrhea, few studies in the field of dysentery have found beneficial effects of probiotics. This study is a randomized double-blind clinical trial. The patients were randomly placed into control and case groups. In the intervention group, the patients received probiotics in the form of Kidilact® sachet, which contained high amounts of 7-strain friendly bacteria strains of Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium infantis, Bifidobacterium breve, and Streptococcus thermophiles. On the other hand, the patients in the control group received placebo sachets on a daily basis for 5 days. It is notable that the treatment protocol of acute dysentery was done on both groups. The results of this study showed significant differences in the duration of blood in diarrhea between probiotic consumers (2.62 days) and the control group (3.16 days) (P value = 0.05). Additionally, significant differences in the average length of hospitalization in probiotic consumers (3.16 days) and control (3.66 days), (P value = 0.02) could be claimed that the consumption of probiotics is effective in reducing the duration of dysentery and diarrhea. The results of this study suggest that the use of probiotics can be effective in reducing the duration of blood in diarrhea. This study was also recorded in the Iran center of clinical trials registration database (IRCT2014060617985N1).

Keywords: Bacteria; Bifidobacterium; Diarrhea; Dysentery; Fever; Lactobacillus; Patient; Probiotics; Streptococcus.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bifidobacterium breve
  • Bifidobacterium longum subspecies infantis
  • Diarrhea / therapy
  • Double-Blind Method
  • Dysentery / therapy*
  • Female
  • Hospitalization
  • Humans
  • Iran
  • Lactobacillus acidophilus
  • Lactobacillus casei
  • Lactobacillus delbrueckii
  • Lactobacillus rhamnosus
  • Male
  • Probiotics / administration & dosage*
  • Streptococcus

Associated data

  • IRCT/IRCT2014060617985N1